Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.58 |
| ▸ | ABL1 | P00519 | 3/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.58 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.58 |
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | MET | P08581 | 2/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
| ▸ | PIM1 | P11309 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.58 |
| ▸ | FLT1 | P17948 | 2/20 | 0.58 |
| ▸ | LTK | P29376 | 2/20 | 0.58 |
| ▸ | GRK5 | P34947 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799872 | 0.84 | CRBN (0.51) | GSK3BCDK5ABL1AURKADAPK3 | |
| SCHEMBL725492 | 0.84 | CRBN (0.51) | GSK3BCDK5ABL1AURKADAPK3 | |
| Bromide SCHEMBL4113407 | 0.82 | CRBN (0.50) | GSK3BCDK5ABL1AURKADAPK3 | |
| SCHEMBL727045 | 0.81 | MB (0.41) | GSK3BCDK5ABL1AURKADAPK3 | |
| SCHEMBL1092914 | 0.81 | CRBN (0.43) | GSK3BCDK5ABL1AURKADAPK3 | |
| Hydrochloric Acid SCHEMBL726497 | 0.80 | MB (0.40) | GSK3BCDK5ABL1AURKADAPK3 | |
| SCHEMBL16230866 | 0.80 | AURKA (0.42) | GSK3BCDK5ABL1AURKADAPK3 | |
| SCHEMBL2842191 | 0.80 | DYRK1A (0.39) | GSK3BCDK5ABL1AURKADAPK3 | |
| SCHEMBL23016925 | 0.78 | ABL1 (0.58) | GSK3BCDK5ABL1AURKADAPK3 | |
| SCHEMBL728499 | 0.78 | ABL1 (0.58) | GSK3BCDK5ABL1AURKADAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240425499-A1 | TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1180105-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-02-20 | — | — | EP | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000055159-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | disclosed |
| EP-0737685-B1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999021859-A1 | AZAOXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | WO | disclosed |
| US-5714495-A | ANXIOLYTIC AGENTS, MELATONIN RECEPTORS FOR TREATING PSYCHOLOGICAL DISORDERS AND ANALGESICS, SLEEP DISORDERS | ADIR ET COMPAGNIE (FR) | 1998-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | GSK3B 2071/4885CDK5 1106/4885ABL1 1309/4885 |
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | GSK3B 342/4885CDK5 738/4885ABL1 128/4885 |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CCR6, CCR1, CCR3 | GSK3B 3311/4885CDK5 637/4885ABL1 723/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | GSK3B 766/4885CDK5 93/4885ABL1 445/4885 |
| US-20240425499-A1 | TYRO3 INHIBITORS | TYRO3, TYR, TH | GSK3B 252/4885CDK5 1535/4885ABL1 63/4885 |
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | ULK1, ULK2, ULK3 | GSK3B 1262/4885CDK5 105/4885ABL1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.